

PRESS RELEASE

Date 11 January 2017

Contact Investor Relations: Julien Vignot, Head Investor Relations, Galenica Group

Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group

Subject The Galenica Group is taking over SD wholesaler Pharmapool

Galenica strengthens its logistics business

The Galenica Group is taking over the physicians wholesaler Pharmapool Ltd. through its own pharmaceutical wholesale company Galexis Ltd. The company will continue to offer its services on the market under its current name and for management purposes will be integrated into Galenica Santé as part of the Services Business sector, which will be able to exploit attractive potential synergies in the future.

Following expiry of the deadline for acceptance on 31 August 2016, 100% of the shareholders of Pharmapool Ltd. had accepted the purchase offer from Galexis. At the end of December 2016, the Competition Commission (COMCO) also approved the acquisition without any condition or requirement. The total value of the transaction is CHF 27.9 million was completed at the beginning of January 2017.

This acquisition will strengthen the logistics activities of the Galenica Santé Business unit. Pharmapool complements the portfolio of wholesaler Galexis, and the integration includes attractive potential synergies. Pharmapool will continue to offer its services to all interested market players in the future, while its customers can also benefit from synergies with Galexis over the medium term. The company will remain an independent company within Galenica Santé and will continue to be managed by its current executive committee at Widnau and Heerbrugg (both in the canton of St. Gallen).

Pharmapool in Widnau supplies and supports medical practices with medicines, consumables, laboratory products and furnishings. The company also manages the Pharmapool central pharmacy in Heerbrugg. Founded in 1996, Pharmapool has a staff of some 100 employees and records sales volume of over CHF 100 million.

For further information, please contact:

Media Relations:

Christina Hertig, Head Corporate Communications Tel. +41 58 852 85 17

E-mail: media@galenica.com

Investor Relations:

Julien Vignot, Head Investor Relations Tel. +41 58 852 85 29

E-mail: investors@galenica.com

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Additional information concerning the Galenica Group can be found at www.galenica.com.

Galenica Ltd.
P.O. Box · Untermattweg 8 · CH-3001 Bern
Phone +41 58 852 85 17 · Fax +41 58 852 85 58
media@galenica.com · www.galenica.com